LTA and neoplasm: TNF has been shown to induce resistance to immunotherapies and acts as a negative biomarker for prognosis. TNFα increases the expression of PD-L1 in tumor cells. Studies have also shown that a TNF-β blockade combined with ICI, such as anti-PD1, has a better therapeutic effect than ICI therapy alone [37].